Portale di Ateneo - En.Unibs.it

Publications containing SPR Anaylisis - Macromolecular Interaction Analysis Unit

  1. B. MARGOSIO et al. “Thrombospondin-1 as a scavenger for matrix-associated fibroblast growth factor-2” Blood, 2003, 102:4399-406(I.F. 9.06) [pubmed]
  2. C. URBINATI et al.“Chemically sulfated Escherichia coli K5 polysaccharide derivatives selectively inhibits HIV-1 Tat biological activities in vitro and in vivo” FEBS Letters, 2004, 568:171-7 (I.F. 3.589)  [pubmed]
  3. M. PRESTA et al. “Anti-angiogenic activity of semi-synthetic biotechnological heparins: LMW sulfated Escherichia coli K5 polysaccharide derivatives as FGF2 antagonists” Arterios. Thromb. & Vascul. Biol. 2005, 25:71-6 (I.F. 6.338) [pubmed]
  4. C.  Pisano et al. “Undersulfated, low molecular weight glycol-split heparin as an antiangiogenic VEGF antagonist” Glycobiology, 2005, 15:1C-6C (I.F. 3.537) [pubmed]
  5. KRICHEVSKY et al. ”The NLS of the HIV-1 Tat protein interacts with the fd bacteriophage and with a peptide derived from its p8 protein” Antiviral Res. 2005, 66:67-78 (I.F. 3.925) [pubmed]
  6. P. JEANNIN et al. “Complexity and complementarity of outer membrane protein-A recognition by cellular and humoral innate immunity receptors” Immunity, 2005, 22:551-60 (I.F. 19.795) [pubmed]
  7. C. URBINATI et al.“avb3 integrin-dependent activation of focal adhesion kinase mediates NFkB  activation and motogenic activity by HIV-1 Tat in endothelial cells” J. Cell Science, 2005, 118:3949-58 (I.F. 5.877) [pubmed]
  8. J. ROSENBLUH et al. “Positively charged peptides can interact with each other as revealed by solid phase binding assays” Analyt. Biochem. 2006, 352:157-68  (I.F. 2.582) [pubmed]
  9. M. CAMOZZI et al. “Identification of an anti-angiogenic FGF2-binding site in the n-terminal extension of the soluble pattern recognition receptor long-pentraxin PTX3” J. Biol. Chem. 2006, 281:22605-13 (I.F. 4.651) [pubmed]
  10. J. BALZARINI et al. “Pradamicin A: a new therapeutic concept for tretment of virus infections with a glycosilated envelope such as human immunodeficiency virus” J. Virol. 2007, 81:362-73 (I.F. 5.076) [pubmed]
  11. BUGATTI et al. “Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of HIV-1 Tat and gp120 proteins” Antimicrobial Agents & Chemother. 2007, 51:2337-45 (I.F. 4.565) [pubmed]
  12. MARGOSIO et al. “Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain” Int. J. Biochem. & Cell Biol. 2008, 40:700-9 (I.F. 4.152) [pubmed]
  13. Lembo et al. “Sulfated K5 Escherichia coli polysaccharide derivatives as wide range inhibitors of genital types of human papillomavirus” Antimicrobial Agents & Chemother. 2008, 52:1374-81 (I.F. 4.565) [pubmed]
  14. M. RUSNATI et al. “Exploiting surface plasmon resonance technology for the identification of fibroblast growth factor 2 (FGF2) antagonists endowed with antiangiogenic activity” Sensors, 2009, 9:6471-503, (I.F. 1.953) [pubmed]
  15. C. URBINATI et al. “HIV-1 Tat and heparan sulfate proteoglycans: a novel mechanism of  lymphocyte adhesion and migration across the endothelium” Blood, 2009, 114:3335-42 (I.F. 9.06) [pubmed]
  16. Bugatti et al. “BSA conjugates bearing multiple copies of the basic domain of  HIV-1 Tat: prototype for the development of multitarget inhibitors of extracellular Tat” Antiviral Res. 2010, 87: 30-9(I.F. 3.925) [pubmed]
  17. M. Donalisio et al.“Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses” Antimicrobial Agents & Chemother. 2010, 54: 4290-99. (I.F. 4.565) [pubmed]
  18. D. Leali et al. “Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide” J Cell Mol Med., 2010 14:2109-29 (I.F. 4.125) [pubmed]
  19. R. RONCA et al. “Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1” Mol. Cancer Ther. 2012, 9:3244-53(I.F. 5.599) [pubmed]
  20. M. DETTIN et al. “Chemoselective surface immobilization of proteins through a cleavable peptide” Bioconjugate Chem. 2011, 21:1753-57 (I.F. 4.58)[pubmed]
  21. P. Chiodelli et al. “Heparan sulfate proteoglycans mediate the angiogenic activity of the novel VEGFR2 agonist gremlin” Arterios. Thromb. & Vascul. Biol. 2011, 31: e116-27 (I.F. 6.338) [pubmed]
  22. C. GIAGULLI et al. “HIV-1 matrix protein p17 is a chemoattractant for monocytes and displays IL-8-like activities by binding to the IL-8 receptor” Blood,2012, 119:2274-83(I.F. 9.06) [pubmed]
  23. K. PAGANO et al. “Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrmobospondin-1-mimic small molecule” Plos One, 2012, 7:e36990 (I.F. 3.73) [pubmed]
  24. P. Chiodelli et al. “Sialic acid associated to avb3 integrin mediates HIV-1 Tat interaction and endothelial cell proangiogenic activation” J. Biol. Chem. 2012, 287:20456-20466 (I.F. 4.651) [pubmed]
  25. F. CACCURI et al. “HIV-1 matrix protein p17 is a pro-angiogenic chemokine acting via CXCR1/CXCR2-mediated activation of Akt-dependent ERK signaling” Proc. Nat. Acad. Sci. USA, 2012, 109:14580-5(I.F. 9.737) [pubmed]
  26. M. RUSNATI  “The impact of surface plasmon resonance in virology” J. Bioengineering & Biomed. Sci. 2012, 2:1000e108
  27. S. MARCHIO’  et al. “A complex of a6 integrin and E-cadherin drives the liver metastasis of colorectal cancer cells by a physical and functional interaction with hepatic angiopoietin-like 6” EMBO Mol. Med. 2012, 4:1-20 (I.F. 7.795) [pubmed]
  28. D. MAIOLO et al. “Role of nanomechanics in canonical and noncanonical pro-angiogenic ligand/VEGF receptor-2 activation” J. Am. Chem. Soc. 2012, 134:14573-9 (I.F. 10.677) [pubmed]
  29. S. Liekens et al. “The thymidine phosphorylase inhibitor 5'-O-tritylinosine (KIN59) is an anti-angiogenic multi-target fibroblast growth factor-2 antagonist” Mol Cancer Ther. 2012, 11:817-29  (I.F. 5.226) [pubmed]
  30. Bugatti et al. “Biochemical characterization of HIV-1 matrix protein p17 interaction with heparin” J. Biol. Chem. 2013 288:1150-1161 (I.F. 4.651) [pubmed]
  31. MATTE et al. “N-terminal cytoplasmic domain of band 3 is required for membrane association of peroxiredoxin-2 in red cells” Free Radical Biol. & Med. 2013, 55:27-35 (I.F. 5.271) [pubmed]
  32. F. Giavazzi et al. “Multi-spot, label-free biodetection at a phantom plastic-water interface” Proc. Nat. Acad. Sci. USA, 2013, 110:9350-9355 (I.F. 9.737)[pubmed]
  33. M. RUSNATI et al.“Moving forward in biosensing technology“ J. Bioengineering & Biomed. Sci. 2013, 3:1000e116
  34. Bon et al. “Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of HIV-1 strains”Plos One, 2013 8:e76842 (I.F. 3.73)[pubmed]
  35. M. Rusnati et al. “Bridging the past and the future of virology: Surface plasmon resonance as a powerful tool to investigate virus/host interactome” Critical Rev. Microbiol. 2013, in press (I.F. 5.065)[pubmed]
  36. D. Petti et al. “Functionalization of gold surfaces with copoly(DMA-NAS-MAPS)” Sensor & actuators: B chemical, 2013, in press (I.F. 3.535)
  • icona che rimanda a facebook
  • icona che rimanda a twitter
  • icona che rimanda a YouTube
  • icona che rimanda a Instagram
  • Logo attestante il superamento, ai sensi della Legge n. 4/2004, della verifica tecnica di accessibilità.
  • Amministrazione trasparente